Literature DB >> 35961653

Signature Effects of Vector-Guided Systemic Nano Bioconjugate Delivery Across Blood-Brain Barrier of Normal, Alzheimer's, and Tumor Mouse Models.

Liron L Israel1, Anna Galstyan1, Alysia Cox1, Ekaterina S Shatalova1, Tao Sun1, Mohammad-Harun Rashid1, Zachary Grodzinski1, Antonella Chiechi1, Dieu-Trang Fuchs1, Rameshwar Patil1, Maya Koronyo-Hamaoui2, Keith L Black1, Julia Y Ljubimova3, Eggehard Holler3.   

Abstract

The ability to cross the blood-brain barrier (BBB) is critical for targeted therapy of the central nerve system (CNS). Six peptide vectors were covalently attached to a 50 kDa poly(β-l-malic acid)-trileucine polymer forming P/LLL(40%)/vector conjugates. The vectors were Angiopep-2 (AP2), B6, Miniap-4 (M4), and d-configurated peptides D1, D3, and ACI-89, with specificity for transcytosis receptors low-density lipoprotein receptor-related protein-1 (LRP-1), transferrin receptor (TfR), bee venom-derived ion channel, and Aβ/LRP-1 related transcytosis complex, respectively. The BBB-permeation efficacies were substantially increased ("boosted") in vector conjugates of P/LLL(40%). We have found that the copolymer group binds at the endothelial membrane and, by an allosterically membrane rearrangement, exposes the sites for vector-receptor complex formation. The specificity of vectors is indicated by competition experiments with nonconjugated vectors. P/LLL(40%) does not function as an inhibitor, suggesting that the copolymer binding site is eliminated after binding of the vector-nanoconjugate. The two-step mechanism, binding to endothelial membrane and allosteric exposure of transcytosis receptors, is supposed to be an integral feature of nanoconjugate-transcytosis pathways. In vivo brain delivery signatures of the nanoconjugates were recapitulated in mouse brains of normal, tumor (glioblastoma), and Alzheimer's disease (AD) models. BBB permeation of the tumor was most efficient, followed by normal and then AD-like brain. In tumor-bearing and normal brains, AP2 was the top performing vector; however, in AD models, D3 and D1 peptides were superior ones. The TfR vector B6 was equally efficient in normal and AD-model brains. Cross-permeation efficacies are manifested through modulated vector coligation and dosage escalation such as supra-linear dose dependence and crossover transcytosis activities.

Entities:  

Keywords:  Alzheimer’s disease; blood-brain barrier; brain tumor; nanocarriers; receptor mediated transcytosis; shuttle peptides; vector

Year:  2022        PMID: 35961653      PMCID: PMC9413444          DOI: 10.1021/acsnano.1c10034

Source DB:  PubMed          Journal:  ACS Nano        ISSN: 1936-0851            Impact factor:   18.027


  98 in total

Review 1.  Nanotechnological advances for the delivery of CNS therapeutics.

Authors:  Ho Lun Wong; Xiao Yu Wu; Reina Bendayan
Journal:  Adv Drug Deliv Rev       Date:  2011-11-07       Impact factor: 15.470

2.  Oral treatment with the d-enantiomeric peptide D3 improves the pathology and behavior of Alzheimer's Disease transgenic mice.

Authors:  Susanne Aileen Funke; Thomas van Groen; Inga Kadish; Dirk Bartnik; Luitgard Nagel-Steger; Oleksandr Brener; Torsten Sehl; Renu Batra-Safferling; Christine Moriscot; Guy Schoehn; Anselm H C Horn; Andreas Müller-Schiffmann; Carsten Korth; Heinrich Sticht; Dieter Willbold
Journal:  ACS Chem Neurosci       Date:  2010-08-02       Impact factor: 4.418

Review 3.  Targeting receptor-mediated transport for delivery of biologics across the blood-brain barrier.

Authors:  Jason M Lajoie; Eric V Shusta
Journal:  Annu Rev Pharmacol Toxicol       Date:  2014-10-08       Impact factor: 13.820

4.  Use of LDL receptor-targeting peptide vectors for in vitro and in vivo cargo transport across the blood-brain barrier.

Authors:  Yves Molino; Marion David; Karine Varini; Françoise Jabès; Nicolas Gaudin; Aude Fortoul; Karima Bakloul; Maxime Masse; Anne Bernard; Lucile Drobecq; Pascaline Lécorché; Jamal Temsamani; Guillaume Jacquot; Michel Khrestchatisky
Journal:  FASEB J       Date:  2017-01-20       Impact factor: 5.191

5.  Large amino acid transporter 1 mediated glutamate modified docetaxel-loaded liposomes for glioma targeting.

Authors:  Lin Li; Xingsheng Di; Shenwu Zhang; Qiming Kan; Hao Liu; Tianshu Lu; Yongjun Wang; Qiang Fu; Jin Sun; Zhonggui He
Journal:  Colloids Surf B Biointerfaces       Date:  2016-01-23       Impact factor: 5.268

6.  Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates.

Authors:  Y Joy Yu; Jasvinder K Atwal; Yin Zhang; Raymond K Tong; Kristin R Wildsmith; Christine Tan; Nga Bien-Ly; Maria Hersom; Janice A Maloney; William J Meilandt; Daniela Bumbaca; Kapil Gadkar; Kwame Hoyte; Wilman Luk; Yanmei Lu; James A Ernst; Kimberly Scearce-Levie; Jessica A Couch; Mark S Dennis; Ryan J Watts
Journal:  Sci Transl Med       Date:  2014-11-05       Impact factor: 17.956

7.  Structure-based ligand discovery for the Large-neutral Amino Acid Transporter 1, LAT-1.

Authors:  Ethan G Geier; Avner Schlessinger; Hao Fan; Jonathan E Gable; John J Irwin; Andrej Sali; Kathleen M Giacomini
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-18       Impact factor: 11.205

8.  Nanobiopolymer for direct targeting and inhibition of EGFR expression in triple negative breast cancer.

Authors:  Satoshi Inoue; Rameshwar Patil; Jose Portilla-Arias; Hui Ding; Bindu Konda; Andres Espinoza; Dmitriy Mongayt; Janet L Markman; Adam Elramsisy; H Westley Phillips; Keith L Black; Eggehard Holler; Julia Y Ljubimova
Journal:  PLoS One       Date:  2012-02-15       Impact factor: 3.240

Review 9.  Smuggling Drugs into the Brain: An Overview of Ligands Targeting Transcytosis for Drug Delivery across the Blood-Brain Barrier.

Authors:  Julia V Georgieva; Dick Hoekstra; Inge S Zuhorn
Journal:  Pharmaceutics       Date:  2014-11-17       Impact factor: 6.321

Review 10.  Lipofuscin, lipofuscin-like pigments and autofluorescence.

Authors:  G Di Guardo
Journal:  Eur J Histochem       Date:  2015-02-06       Impact factor: 3.188

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.